Short description
Overcoming current limitations of small molecule drug discovery using proprietary structural biology technology and generative AI.
Description
CrystalsFirst's MAGNET platform overcomes current limitations of small molecule drug discovery. The integration of high-performance structural biology detects molecular magnets and generative AI/Machine Learning identifies novel molecules and druggable binding pockets for difficult targets.
Our MAGNET Platform is a unique and powerful approach to unlock chemical matter. It integrates the “crystal structure first” strategy, large-scale computational modelling, generative AI and medicinal chemistry. Starting with crystal structures as the first step in drug discovery, we also gain valuable insights into target interactions, enabling rational design from the beginning. Building block chemistry provides rapid access to diverse chemical scaffolds, facilitating hit expansion, scaffold hopping, and efficient compound generation. Computational modelling and machine learning aid in predicting compound properties and optimizing lead candidates.
The synergistic combination of these elements in the MAGNET Platform accelerates the discovery process and increases the likelihood of finding innovative and effective therapeutic compounds.
Last funding
Cannot Access
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Marburg, Hessen, Germany, Europe
Founded on
February 28, 2018
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Investors
Noaccessforu, Noaccess, Nopepepe, Noaccessforu
Sign in for full access
Founders
Serghei Glinca, Stefan Merkl